Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 246 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading MOST POPULAR Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... December 7, 2021 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 Load more HOT NEWS ESMO Welcomes European Parliament Resolution Marking World Cancer Day Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects Spending Review 2020 – Steps in the right direction, but opportunities...
